Imaging study of a new tracer for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study uses a special imaging scan (PET/CT) with a tracer to see how a drug called ivonescimab attaches to your cancer. It's not a treatment — it helps doctors understand your cancer better without needing a biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have esophageal cancer (a cancer of the food pipe).
- You need to be 18 years or older.
- You cannot have had any cancer treatment (like chemo or radiation) before the scan.
- You cannot have had major surgery in the last 3 months.
- You must be able to lie still for a PET/CT scan safely.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ivonescimab combined with standard chemotherapy (FOLFOX) for people with advanced adenocarcinoma of the esophagus, stomach, or gastroesophageal junction. The drug is designed to help the immune system fight cancer. The study is for people who have not had prior treatment for stage IV disease and whose cancer is HER2 negative.
This study tests whether a special imaging scan (functional imaging) can identify which esophageal cancers respond best to radiation. If you have stage II–IVA esophageal cancer and meet the health criteria, joining may help personalize your treatment.
This trial tests a new drug called Ivonescimab (AK112) combined with two chemotherapy drugs (Abraxane and cisplatin) given before surgery for esophageal cancer. The goal is to see if this combination can shrink tumors and improve surgery outcomes for patients with locally advanced disease.
This study tests a new combination of medications to keep stage III lung cancer from coming back after initial radiation and chemotherapy. It aims to see if this approach can help people live longer without their cancer returning.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
This Phase 1 study uses specialized imaging (including MRI) to better “see” low-oxygen areas in esophageal cancer and help guide individualized radiation treatment. It aims to improve how radiation is planned and delivered while checking safety.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.